The current role of sublingual immunotherapy in the treatment of allergic rhinitis in adults and children

Journal of Asthma and Allergy

Volumn , Issue 4, 2011, Pages 13-17

  Incorvaia, Cristoforo ^a   Masieri, Simonetta ^b   Scurati, Silvia ^c   Soffia, Silvia ^c   Puccinelli, Paola ^c   Frati, Franco ^c  

^a Istituti Clinici di Perfezionamento   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c Medical and Scientific Department   (Italy)

Author keywords

Allergic rhinitis; Compliance; Efficacy; Meta analysis; Safety; Sublingual immunotherapy

Indexed keywords

GRASS POLLEN EXTRACT; IMMUNOMODULATING AGENT; PLACEBO; POLLEN ANTIGEN;

ADULT; ALLERGIC RHINITIS; ASTHMA; CHILD; CLINICAL FEATURE; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; EAR PRURITUS; EVIDENCE BASED MEDICINE; GASTROINTESTINAL DISEASE; HUMAN; IMMUNOTHERAPY; LOW DRUG DOSE; MOUTH DISEASE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT EDUCATION; PRURITUS; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT ALLERGY; REVIEW; RHINITIS; RHINOCONJUNCTIVITIS; TABLET FORMULATION; THROAT IRRITATION; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING;

EID: 79953144959     PISSN: 11786965     EISSN: None     Source Type: Journal    
DOI: 10.2147/JAA.S16632     Document Type: Review

References (41)

1. Asher MI, Montfort S, Björkstén B, et al; ISAAC Phase Three Study Group. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross-sectional surveys. Lancet. 2006; 368:733-743.
2. Canonica GW, Bousquet J, Mullol J, et al. A survey of the burden of allergic rhinitis in Europe. Allergy. 2007;62:17-25.
3. Bousquet J, van Cauwenberge P, editors. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108(Suppl. 5):147-334.
4. Harmsen L, Nolte H, Backer V. The effect of generalist and specialist care on quality of life in asthma patients with and without allergic rhinitis. Int Arch Allergy Immunol. 2010;152:288-294.
5. Bousquet J, Lockey R, Malling HJ, editors. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO Position Paper. J Allergy Clin Immunol. 1998;102:58-62.
6. Lockey RF, Benedikt LM, Turkeltaub PC, et al. Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol. 1987; 79:660-677.
7. Canonica GW, Passalacqua G. Noninjection routes for immunotherapy. J Allergy Clin Immunol. 2003;111:437-448.
8. Scadding GK, Brostoff J. Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite. Clin Allergy. 1986; 16:483-491.
9. Tari MG, Mancino M, Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite: a doubleblind study. Allergol Immunopathol. 1990;18:277-284.
10. Wilson DR, Torres-Lima M, Durham S. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy. 2005; 60:4-12.
11. Olaguibel JM, Alvarez Puebla MJ. Efficacy of sublingual allergen vaccination for respiratory allergy in children: conclusions from one meta-analysis. J Investig Allergol Clin Immunol. 2005;15:9-16.
12. Penagos M, Compalati E, Tarantini F, et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3-18 years of age: a meta analysis of randomized placebo-controlled, double blind trials. Ann Allergy Asthma Immunol. 2006;97:141-148.
13. Compalati E, Passalacqua G, Bonini M, Canonica GW. The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis. Allergy. 2009;64:1570-1579.
14. Di Bona D, Plaia A, Scafidi V, et al. Efficacy of sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a systematic review and meta-analysis. J Allergy Clin Immunol. 2010;126:558-566.
15. Nieto A, Mazon A, Pamies R, et al. Sublingual immunotherapy for allergic respiratory diseases: an evaluation of meta-analyses. J Allergy Clin Immunol. 2009;124:157-161.
16. Compalati E, Penagos M, Tarantini D, et al. Specific immunotherapy for respiratory allergy: state of the art according to current meta-analyses. Ann Allergy Asthma Immunol. 2009;102:22-28.
17. Durham SR, Yang WH, Pedersen MR, et al. Sublingual immunotherapy with once daily grass allergen tablet: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006; 117:802-809.
18. Didier A, Malling HJ, Worm M, et al. Optimal dose, efficacy, and safety of once daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol. 2007; 120:1338-1345.
19. Wahn U, Tabar A, Kuna P, et al; SLIT Study Group. Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2009;123:160-166.
20. Canonica GW, Bousquet J, Casale T, et al. Sublingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy. 2009; 64(Suppl 91):1-59.
21. Devillier P, Brehler R, Sastre J, et al. The clinical development of specific immunotherapies: specific methodological issues and clinical interpretation of results. Allergy. 2010;65(Suppl 92):567.
22. Andrè C, Vatrinet C, Galvain S. Safety of sublingual swallow immunotherapy in children and adults. Int Arch Allergy Immunol. 2000; 121:220-234.
23. Rienzo VD, Minelli M, Musarra A, et al. Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years. Clin Exp Allergy. 2005;35:560-564.
24. Gidaro GB, Marcucci F, Sensi L, et al. The safety of sublingual-swallow immunotherapy: an analysis of published studies. Clin Exp Allergy. 2005;35:565-571.
25. Passalacqua G, Guerra L, Compalati E, Canonica GW. The safety of allergen specific sublingual immunotherapy. Curr Drug Saf. 2007; 2:117-123.
26. Kleine-Tebbe J, Ribel M, Herold DA. Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial. Allergy. 2006;61:181-184.
27. Frati F, Sensi L, di Rienzo V, et al. A model for management of sublingual immunotherapy. Eur Ann Allergy Clin Immunol. 2003; 35:56-60.
28. André C, Fadel R. Anaphylaxis caused by allergen sublingual immunotherapy? Allergy. 2007;62:1220-1221.
29. De Groot H, Bijl A. Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet. Allergy. 2009;64:963-964.
30. Cochard MM, Eigenmann PA. Sublingual immunotherapy is not always a safe alternative to subcutaneous immunotherapy. J Allergy Clin Immunol. 2009;124:378-379.
31. Incorvaia C, Mauro M. Do indications to sublingual immunotherapy need to be revised? J Allergy Clin Immunol. 2010;125:277-278.
32. Larsen TH, Poulsen LK, Melac M, et al. Safety and tolerability of grass pollen tablets in sublingual immunotherapy: a phase 1 study. Allergy. 2006;61:1173-1176.
33. Incorvaia C, Mauro M, Ridolo E, et al. Patient's compliance with allergen immunotherapy. Patient Prefer Adherence. 2008;2:247-251.
34. Passalacqua G, Frati F, Puccinelli P, et al. Adherence to sublingual immunotherapy: the allergist's viewpoint. Allergy. 2009;64:1796-1797.
35. Novembre E, Galli E, Landi F, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2004;114:851-857.
36. Incorvaia C, Rapetti A, Scurati S, et al. Importance of patient's education in favouring compliance with sublingual immunotherapy. Allergy. 2010;65:1341-1342.
37. Tahamiler R, Saritzali G, Canakcioglu S. Long-term efficacy of sublingual immunotherapy in patients with perennial rhinitis. Laryngoscope. 2007;117:965-969.
38. Marogna M, Spadolini I, Massolo A, et al. Long-lasting effects of sublingual immunotherapy accordino to its duration: a 15-year prospective study. J Allergy Clin Immunol. 2010;126:969-975.
39. Berto P, Frati F, Incorvaia C. Economic studies of immunotherapy: a review. Curr Opin Allergy Clin Immunol. 2008;8:585-589.
40. Incorvaia C, Frati F, Puccinelli P, et al. Effects of sublingual immunotherapy on allergic inflammation. Inflamm Allergy Drug Targets. 2008; 7:167-172.
41. Durham SR, Emminger W, Kapp A, et al. Long-term clinical efficacy in grass-pollen induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol. 2010;125:131-138.